Opinion

Video

Future Perspectives in the Treatment of Polycythemia Vera

Author(s):

John Mascarenhas, MD,Joe Scandura, MD, PhD

John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
3 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Anthony M. Hunter, MD
Related Content
Naseema Gangat, MBBS, of Mayo Clinic
January 10th 2025

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

MDS | Maris– stock.adobe.com
January 7th 2025

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Imetelstat Plus Ruxolitinib in Myelofibrosis | Image Credit: © Свет Лана – stock.adobe.com
January 6th 2025

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

stock.adobe.com
December 16th 2024

OB756 Showcases Favorable Tolerability in JAK Inhibitor–Naive Myelofibrosis